Literature DB >> 23196794

Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.

Nelson G Ordóñez1.   

Abstract

Distinguishing between peritoneal epithelioid mesotheliomas and papillary serous carcinomas involving the peritoneum can be difficult on routine histological preparations, but this differential diagnosis can be facilitated by the use of immunohistochemistry. Recent investigations have indicated that PAX8, PAX2, claudin-4, and h-caldesmon are immunohistochemical markers that can assist in distinguishing between these two malignancies; however, much of the information published on the value of these markers is either insufficient or contradictory. The purpose of this study is to resolve some of the existing controversies and to fully determine the practical value of these markers for assisting in the differential diagnosis between peritoneal mesotheliomas and serous carcinomas. In order to do so, a total of 40 peritoneal epithelioid mesotheliomas and 45 serous carcinomas (15 primary, 30 metastatic to the peritoneum) were investigated. PAX8 and PAX2 nuclear positivity was demonstrated in 42 (93%) and 25 (56%) of the serous carcinomas, respectively, whereas none of the mesotheliomas expressed either marker. Forty-four (98%) of the serous carcinomas exhibited claudin-4 reactivity along the cell membrane, whereas none of the mesotheliomas were positive for this marker. All of the serous carcinomas and mesotheliomas were negative for h-caldesmon. Based on these results, it is concluded that PAX8 and claudin-4 have a higher sensitivity and specificity for assisting in discriminating between peritoneal epithelioid mesotheliomas and serous carcinomas when compared with all of the other positive carcinoma markers that are, at present, recommended to be included in the immunohistochemical panels used in this differential diagnosis. Even though it is highly specific, PAX2 has little practical value in the diagnosis of peritoneal epithelioid mesotheliomas as its sensitivity is low. The h-caldesmon is not useful.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23196794     DOI: 10.1038/modpathol.2012.200

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  The diagnostic role of PTEN and ARID1A in serous effusions.

Authors:  Ben Davidson; Maurizio Pinamonti; Dolors Cuevas; Arild Holth; Pio Zeppa; Thomas Hager; Jeremias Wohlschlaeger; Martin Tötsch
Journal:  Virchows Arch       Date:  2017-11-24       Impact factor: 4.064

Review 2.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

3.  The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases.

Authors:  Kohei Nakamura; Kentaro Nakayama; Risa Nagaoka; Kiyoka Nishisako; Masako Ishikawa; Hiroshi Katagiri; Tomoka Ishibashi; Emi Sato; Chika Amano; Satoru Kyo
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

Review 4.  Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review.

Authors:  Jingping Yuan; Liang He; Bing Han; Yan Li
Journal:  World J Surg Oncol       Date:  2017-04-11       Impact factor: 2.754

5.  Clinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion.

Authors:  Guan-Ying Ma; Shuai Shi; Ping Wang; Xing-Guang Wang; Zhi-Gang Zhang
Journal:  Biomed Rep       Date:  2022-06-07

Review 6.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

7.  PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer.

Authors:  Hong-Juan Chai; Qing Ren; Qin Fan; Liu Ye; Guang-Ye Du; Hua-Wen Du; Wei Xu; Yue Li; Lan Zhang; Zhong-Ping Cheng
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

Review 8.  Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Authors:  Stergios Boussios; Michele Moschetta; Afroditi Karathanasi; Alexandros K Tsiouris; Foivos S Kanellos; Konstantina Tatsi; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2018-09-14

Review 9.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Aliya N Husain; Thomas Krausz
Journal:  Transl Lung Cancer Res       Date:  2020-02

10.  Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.

Authors:  Kenzo Hiroshima; Di Wu; Eitetsu Koh; Yasuo Sekine; Daisuke Ozaki; Toshikazu Yusa; Tadao Nakazawa; Shoutaro Tsuji; Yohei Miyagi; Ann E Walts; Alberto M Marchevsky; Aliya N Husain; Kohzoh Imai
Journal:  Pathol Int       Date:  2021-07-09       Impact factor: 2.534

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.